How to buy Incyte Corporation (INCY) stocks

Incyte Corporation is a biotechnology business based in the US. Incyte Corporation shares (INCY) are listed on the NASDAQ and all prices are listed in US Dollars.

Its last market close was $68.84 – a decrease of 1.38% over the previous week. Incyte Corporation employs 2,524 staff and has a trailing 12-month revenue of around $4.1 billion.

Our top picks for where to buy Incyte Corporation stock

Buy Incyte Corporation stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Incyte Corporation stock price (NASDAQ: INCY)

Use our graph to track the performance of INCY stocks over time.

Incyte Corporation stocks at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$68.84
52-week range	$50.35 - $83.95
50-day moving average more info button	$72.10
200-day moving average more info button	$63.20
Wall St. target price	$79.30
PE ratio more info button	750.5555
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$0.09

Is it a good time to buy Incyte Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Incyte Corporation price performance over time

Historical closes compared with the close of $68.84 from 2024-12-20

1 week (2024-12-16)	-1.38%
1 month (2024-11-22)	-4.02%
3 months (2024-09-23)	7.36%
6 months (2024-06-21)	8.89%

1 year (2023-12-22)	9.53%
2 years (2022-12-23)	-15.39%
3 years (2021-12-23)	73.47
5 years (2019-12-23)	90.16

Is Incyte Corporation stock undervalued or overvalued?

Valuing Incyte Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Incyte Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Incyte Corporation's P/E ratio

Incyte Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 751x. In other words, Incyte Corporation shares trade at around 751x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stock or simply that they're over-valued.

Incyte Corporation's PEG ratio

Incyte Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.5921. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Incyte Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Incyte Corporation's EBITDA

Incyte Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $80.5 million.

The EBITDA is a measure of a Incyte Corporation's overall financial performance and is widely used to measure a its profitability.

Incyte Corporation financials

Revenue TTM	$4.1 billion
Operating margin TTM	14.96%
Gross profit TTM	$1.6 billion
Return on assets TTM	-0.12%
Return on equity TTM	0.8%
Profit margin	0.8%
Book value	$16.45
Market Capitalization more info button	$13 billion

TTM: trailing 12 months

Incyte Corporation stock dividends

We're not expecting Incyte Corporation to pay a dividend over the next 12 months.

Have Incyte Corporation's stocks ever split?

Incyte Corporation's stocks were split on a 2:1 basis on 31 August 2000 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Incyte Corporation stocks – just the quantity. However, indirectly, the new 50% lower stock price could have impacted the market appetite for Incyte Corporation stocks, which in turn could have impacted Incyte Corporation's stock price.

Incyte Corporation stock price volatility

Over the last 12 months, Incyte Corporation's stocks have ranged in value from as little as $50.3498 up to $83.95. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Incyte Corporation's is 0.71. This would suggest that Incyte Corporation's stocks are less volatile than average (for this exchange).

Incyte Corporation overview

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Incyte Corporation is owned by insiders or institutions?
Currently 2.037% of Incyte Corporation stocks are held by insiders and 97.712% by institutions. How many people work for Incyte Corporation?
Latest data suggests 2,524 work at Incyte Corporation. When does the fiscal year end for Incyte Corporation?
Incyte Corporation's fiscal year ends in December. Where is Incyte Corporation based?
Incyte Corporation's address is: 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803 What is Incyte Corporation's ISIN number?
Incyte Corporation's international securities identification number is: US45337C1027 What is Incyte Corporation's CUSIP number?
Incyte Corporation's Committee on Uniform Securities Identification Procedures number is: 45337C102

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.